Key takeaways for New Jersey
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • NJ FamilyCare coverage rules apply for Cardiovascular Risk Reduction patients in New Jersey — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
New Jersey-specific context
New Jersey has telehealth access concentrated in Newark, Jersey City, Paterson metros, with additional reach to Elizabeth and Edison. RWJBarnabas Health, Hackensack Meridian Health, Atlantic Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nj.gov/health.
New Jerseytelehealth & pricing rules
- • New Jersey requires a live video consultation before a GLP-1 prescription.
- • New Jersey allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Jersey: ~$328/mo (compounded options often lower, brand higher).